Overview

P2X7 Receptor Antagonists Market Overview:

P2X7 receptor, an ATP-gated and non-selective cation channel that can regulate inflammatory disease has been implicated. The release of pro-inflammatory cytokines can be caused by the activation of the P2X7 channel by high levels of adenosine triphosphate (ATP). This has been linked to a wide range of diseases. There is currently no P2X7 antagonist on the market. Clinical trials have not yet begun to identify any P2X7 antagonists. P2X7R, a subtype of the seven purinergic P2X7 receptors that are ATP-gated, non-selective Cation Channels, is unique. There have been reports that P2X7R plays a pathological role in a variety of diseases, including arthritis, inflammatory bowel disease, neurodegenerative disorders, chronic pain, mood disorders, and cancers. Many pharmaceutical companies have attempted to develop a clinical candidate for P2X7R.
P2X7 receptor, an ATP-gated and non-selective cation channel, is associated with a variety of inflammatory disorders. P2X7 receptor antagonists are therapeutic agents. Pain management is a common use of opioid medications. P2X7R, a subtype of the seven purinergic P2X receptors (ATP-gated nonselective Cation Channels), is unique. The pathological role of P2X7R in various diseases has been documented, including neurodegenerative diseases and chronic pain, mood disorders, cancers, and arthritis. A P2X7 Receptor Antagonist, or RA, is a pain medication that blocks the brain's activity of the ligand. The P2X7 Receptor is an important molecule that initiates inflammatory processes within the body.

The approval and launch of an alternative pain management option are expected to be a breakthrough in this space. P2X7 has been linked to major depression. Animal studies have also shown that P2X7 antagonists can cause P2X7 to act in a way similar to antidepressants. Inflammation, mood disorders, and depression are all possible areas where P2X7 may be involved. Its antagonism could also help to modify treatment. Numerous research studies have shown that P2X7 channels are activated by the pro-inflammatory cytokines IL-1b, and IL-18. Extracellular ATP has a low affinity for P2X7, compared to other purinergic ion channel channels (P2X4, P2X3, etc.). The therapeutic benefits of P2X7 receptor antagonists are significant, since P2X7 receptors are associated with inflammation regulation, and all immune cells (lymphocytes macrophages monocytes, and lymphocytes) express P2X7.

FutureWise Market Research has instantiated a report that provides an intricate analysis of P2X7 Receptor Antagonists Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the P2X7 Receptor Antagonists Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.


Major players included in the P2X7 Receptor Antagonists Market:
• GlaxoSmithKline Plc
• Johnson and Johnson
• AstraZeneca Plc
• RaQualia Pharma
• Evotec AG
• Asahi Kasei Corporation
• Pfizer
(Note: The list of the major players will be updated with the latest market scenario and trends)


P2X7 Receptor Antagonists Market Segmentation:
By Drug Product
• AKP-23494954/RQ-00466479
• EVT 401
• GSK1482160
• JNJ-55308942
• JNJ-54175446
• Others

By Application
• Central Nervous System Disorders
• Immunological Disorders
• Others

By End-User
• Hospital
• Ambulatory Surgical Center
• Pharmaceutical and Botechnology Companies

By Region
• North America
Europe
• Asia-Pacific
• Latin America
• Middle East and Africa


Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants


FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth


Objectives of the Study:
• To provide with an exhaustive analysis on the P2X7 Receptor Antagonists Market By Drug Product, By Application, By End-User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions


Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

$3450

Need Assistance

--------

UK : +44 141 628 9353
US : +1 347 709 4931

OR

Contact Sales

What you get


  • Excel Dataset

  • Infographics

  • PDF Report

  • Market Overview

  • PowerPoint Presentation

What's included


  • Consumer Perception and Procurement

  • Competitive Analysis

  • What’s Next

  • Market Data Forecast

  • Risks and Opportunity Assessment

  • Market Trends and Dynamics